Natco Pharma and Breckenridge Pharmaceutical Launch Generic Everolimus Tablets in the U.S.

Natco Pharma Limited, in partnership with Breckenridge Pharmaceutical, Inc., has announced the immediate U.S. launch of generic Everolimus Tablets for Oral Suspension, following final approval from the U.S. Food and Drug Administration (FDA). These tablets, available in 2 mg, 3 mg, and 5 mg strengths, are bioequivalent to Novartis's Afinitor Disperz and are indicated for treating specific tumors in patients aged one year and older with tuberous sclerosis complex (TSC). This launch marks a significant milestone in providing affordable treatment options for pediatric oncology patients.